uniQure N.V. (QURE) - Stock Analysis
Last updated: Mar 9, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong liquidity • High gross margin • Heavy leverage QURE shows ample liquid investments and high gross margins but is undermined by heavy R&D/operating spend, persistent losses, negative free cash flow and substantial long-term debt that make it risky despite trading below tangible book value.
Price Behavior
Key Price Behavior Insights: • Short‑term downtrend • Elevated downside momentum • Buyer interest mid‑$20s Support Level: $9.03–$10.65 Resistance Level: $23–$26 QURE is in a short‑term downtrend, trading well below its last‑month average (~$20.03) after a roughly 40–45% slide from the mid‑20s to single digits in early March, with near‑term support at $9.03–$10.65 and clear resistance at $23–$26 that must be reclaimed to stabilize the bias.
Sentiment & News
Key News Insights: • Plaintiff outreach • Fixed class period • April deadline Multiple plaintiff firms have issued redundant investor alerts alleging securities claims for uniQure purchases from 2025-09-24 to 2025-10-31 and are soliciting lead plaintiffs ahead of a 2026-04-13 court deadline.
AI Summary
uniQure has moved from a binary clinical upside to a capital‑intensive regulatory replay—its valuation now hinges on FDA acceptance of AMT‑130 and near‑term balance‑sheet durability, so monitor upcoming FDA meeting minutes, quarterly cash + short‑term investment trends, and debt/refinancing milestones as concrete re‑rating triggers. #De-risking
Description
uniQure N.V. is a gene therapy company developing treatments for genetic and other severe diseases. Its lead program, etranacogene dezaparvovec (AMT-061), is in the Phase III HOPE-B trial for hemophilia B, and the broader pipeline includes clinical and preclinical candidates targeting central nervous system and neuromuscular disorders such as Huntington’s disease, Parkinson’s disease, temporal lobe epilepsy, ALS and forms of Alzheimer’s, as well as earlier-stage hemophilia approaches. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 29 | Oct 6 | QURE | uniQure N.V. | uniQure’s Phase I/II Huntington’s gene therapy trial showed a 75% slowing of progression, triggering a 250% price surge and near five-year high. Strong FDA alignment for BLA filing and robust capital provide near-term growth catalysts despite technical overbought conditions and dilution risk. | Closed | -10.9% |